Drug Drug Interaction Clinical Trial
Official title:
A Two-arm, Open-label, Single-sequence, Multiple Oral Dosings, Crossover Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of DWC202313 and DWC202314 in Healthy Adult Volunteers
This is A two-arm, open-label, single-sequence, multiple oral dosings, crossover study to evaluate the safety and the pharmacokinetic interaction of DWC202313 and DWC202314 in healthy adult volunteers.
Status | Recruiting |
Enrollment | 32 |
Est. completion date | December 2023 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years to 45 Years |
Eligibility | Inclusion Criteria: - over 19 year old Exclusion Criteria: - Galactose intolerance - Lapp lactase deficiency |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | H Plus YANGJI Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Daewoong Pharmaceutical Co. LTD. |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cmax,ss of DWC202313 and DWC202314 | Up to 14 days | ||
Primary | AUCt,ss of DWC202313 and DWC202314 | Up to 14 days | ||
Secondary | Tmax,ss of DWC202313 and DWC202314 | Up to 14 days | ||
Secondary | Cmin,ss of DWC202313 and DWC202314 | Up to 14 days | ||
Secondary | t1/2 of DWC202313 and DWC202314 | Up to 14 days | ||
Secondary | CLss/F of DWC202313 and DWC202314 | Up to 14 days | ||
Secondary | Vdss/F of DWC202313 and DWC202314 | Up to 14 days | ||
Secondary | PTF of DWC202313 and DWC202314 | Up to 14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05574374 -
Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04557397 -
Fruquintinib CYP3A Inhibitor and Inducer Study
|
Phase 1 | |
Completed |
NCT06031454 -
Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin
|
Phase 1 | |
Completed |
NCT05137600 -
A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05812404 -
Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04606537 -
Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04939467 -
Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04542252 -
Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects
|
Phase 1 | |
Enrolling by invitation |
NCT06037564 -
B-free Multistage Trial
|
Phase 4 | |
Completed |
NCT05123820 -
Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470
|
Phase 1 | |
Recruiting |
NCT04840862 -
Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor
|
Phase 4 | |
Completed |
NCT04814498 -
Drug-Drug Interaction (DDI) Study in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01350921 -
Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03103568 -
A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04840641 -
Flucloxacillin as an Inducer of CYP-enzymes
|
Phase 1 | |
Completed |
NCT05304845 -
Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects
|
Phase 1 | |
Completed |
NCT05860114 -
Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)
|
Phase 1 | |
Completed |
NCT05845567 -
The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)
|
Phase 1 | |
Completed |
NCT04776499 -
Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03909529 -
Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug)
|
Phase 1 |